Nexavar News and Research

RSS
Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

GenSpera presents final data from G-202 Phase I clinical trial at EORTC-NCI-AACR Symposium

GenSpera presents final data from G-202 Phase I clinical trial at EORTC-NCI-AACR Symposium

FDA grants Priority Review designation to sNDA for Nexavar tablets

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Sirtex unveils new website to learn more about SIR-Spheres microspheres

Sirtex unveils new website to learn more about SIR-Spheres microspheres

Viral Genetics changes name to VG Life Sciences

Viral Genetics changes name to VG Life Sciences

Scientists show how sorafenib can be dangerous to the heart

Scientists show how sorafenib can be dangerous to the heart

Financial Times examines legal disputes in India over pharmaceutical patent laws

Financial Times examines legal disputes in India over pharmaceutical patent laws

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

India's CNBC-TV18 examines implications of country's decision to issue compulsory license for Bayer cancer drug

India's CNBC-TV18 examines implications of country's decision to issue compulsory license for Bayer cancer drug

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Viral Genetics initiates Phase 1 trial of MDT compounds for ovarian cancer

Viral Genetics initiates Phase 1 trial of MDT compounds for ovarian cancer

Obama administration's intellectual property policy inflating medical costs abroad

Obama administration's intellectual property policy inflating medical costs abroad

Bayer receives priority review designation from FDA for regorafenib NDA

Bayer receives priority review designation from FDA for regorafenib NDA